Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas

BACKGROUND: Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of patients with positiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Folgiero, Valentina, Avetrani, Paolo, Bon, Giulia, Di Carlo, Selene E., Fabi, Alessandra, Nisticò, Cecilia, Vici, Patrizia, Melucci, Elisa, Buglioni, Simonetta, Perracchio, Letizia, Sperduti, Isabella, Rosanò, Laura, Sacchi, Ada, Mottolese, Marcella, Falcioni, Rita
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2220038/
https://www.ncbi.nlm.nih.gov/pubmed/18270579
http://dx.doi.org/10.1371/journal.pone.0001592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2220038/
https://www.ncbi.nlm.nih.gov/pubmed/18270579
http://dx.doi.org/10.1371/journal.pone.0001592

Ejemplares similares